Clinical Trial Update: Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

This update reports the completion of Phase 1 and Phase 2 clinical trials evaluating dasatinib (Sprycel) in newly diagnosed core-binding factor acute myeloid le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: University of Ulm | Conditions: Acute Myeloid Leukemia (AML) | Phase 1, Phase 2 | Status: COMPLETED